May 23, 2018 – San Diego, Calif. — Access Scientific, LLC announced completion of an in vivo study demonstrating the superior anti-thrombotic (i.e., anti-clotting) property of its unique intravascular catheter material, ChronoFlex C® with BioGUARD™ technology.
The study found that ChronoFlex C with BioGUARD demonstrates thrombo-resistance where it matters most — on the surface of the blood vessel. No other catheter material has demonstrated this clinically important effect.
While other catheter manufacturers claim anti-thrombotic properties that reduce thrombus (clot) formation “on the surface of the catheter,” these anti-thrombotic claims cite in vivo or in vitro studies that show diminished thrombus formation solely on the surface of the catheter. This finding is often and mistakenly conflated with deep vein thrombosis (DVT) – a condition known to be associated with high-risk complications like bloodstream infection or blood clot embolization. There is no evidence that thrombo-resistance on the surface of the catheter has any effect on diminishing DVTs in actual patients.
Today’s announcement may serve to explain, at least in part, why Access Scientific’s POWERWAND™ catheters consistently demonstrate fewer DVTs and fewer total complications (including bloodstream infections) than other catheters used for similar purposes. “We now know it is not just the POWERWAND atraumatic insertion techniques that allow the vessel lining to remain clean and smooth,” said Steve Bierman MD, the company’s Chief Medical Officer. “It is also the catheter material, ChronoFlex C, and our patented BioGUARD processing, that makes POWERWAND anti-thrombotic both on the catheter surface and on the vessel wall.”
As hospitals continue to face the pressures of Value-Based Purchasing, novel products like POWERWAND offer solutions that both improve patient outcomes and reduce overall costs.
Access Scientific said that in the coming months it will reveal results of another completed study (pending publication). Combined with the current announcement of superior anti-thrombogenicity, this next study demonstrate the value of ChronoFlex C with BioGUARD as the ideal material for a wide variety of indwelling vascular catheters.
I guarantee you this news will make your professional life a whole lot easier and even more gratifying.
All over the world, vascular access specialists are now using ultrasound to help insert peripheral IVs (PIVs). Because of this, central line insertions are often avoided and existing central lines are able to be discontinued. That’s the good news.
The bad news is: the median dwell time of ultrasound guided PIVs is 26 hours, and their failure rate is nearly 50%. Ultrasound-guided PIVs just cannot last, they are too short and made of the wrong material (i.e. polyurethane).
Fortunately, Access Scientific has the solution—POWERWAND™ EDC: The first power-injectable, non-trimmable 6cm extended-dwell, 3Fr catheter, specifically designed for ultrasound-guided peripheral IV access. Like all POWERWANDs, the EDC is made of ChronoFlex™C and inserted using either the XL method (easiest) or the accelerated Seldinger technique (fastest).
Does it perform? Preliminary data from a prestigious urban hospital—currently in the process of publishing these remarkable results—revealed the POWERWAND™ EDC average dwell time of 11.2 days. That’s longer than the vast majority of midlines! And, the POWERWAND™ EDC resulted in a 39.1% reduction of central line usage. No other peripheral IV in the world can boast such extraordinary results.
Imagine not having to go back again and again to the same patient to start and restart an ultrasound-guided PIV. Imagine not having to ultimately start a PICC or CVC and risk a CLABSI on that poor patient. Imagine the patient and family sincerely offering you their thanks.
There is a new and better tool in your toolbox—the revolutionary 6cm, 3Fr POWERWAND™ EDC. I’m sure if you try it, you’ll quickly realize it is by far the best peripheral vascular access device ever made.
Steve Bierman MD
Definitive proof has finally arrived. PICCs are no longer required to deliver long-term or short-term vancomycin (4mg/ml). Over 1000 patients, representing over 8000 catheter-days, are reported in this month’s JAVA to have had no DVTs and no bloodstream infections and minimal phlebitis (0.6%) during intravenous vancomycin administration through the POWERWAND midline. (Full article)
What does this groundbreaking study mean for you and your institution?
In most hospitals, vancomycin administration is an indication for about 20% of PICCs. This new POWERWAND study demonstrates that these patients no longer need PICCs, which means you can reduce your central line days by roughly 20%. Instead of a PICC, a 4Fr or 5Fr POWERWAND placed in the deep vessels of the upper arm will get the job done safer and more cost-efficiently. In fact, placing a POWERWAND is usually at least $90.00 less expensive than placing a PICC.
Remember, only the POWERWAND midline has over 20,000 catheter days of published data attesting to zero bloodstream infections and the lowest complication rates of any vascular access device ever studied. (refs) Couple this with the news of safe vancomycin administration (over 5 years, in over 1000 patients) and you really have compelling reasons to support your POWERWAND use.
It’s a pleasure to share this information with you, because it means that everyone—patients and providers—gets to share the benefits POWERWAND use. Thank you for your continued, evidence-based support.
Steve Bierman, MD
Chief Medical Officer